B
AKBA icon

Bailard’s Akebia Therapeutics AKBA Stock Holding History

Bailard’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,900
Closed -$94K – 452
2019
Q4 		$94K Hold
14,900
– – 0.01% 527
2019
Q3 		$58K Hold
14,900
– – ﹤0.01% 526
2019
Q2 		$72K Hold
14,900
– – ﹤0.01% 534
2019
Q1 		$122K Buy
+14,900
New +$102K 0.01% 523

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bailard's AKBA Position: Q1 2020 in Review

Bailard sold out of Akebia Therapeutics (AKBA) in Q1 2020, closing a stake of 14,900 shares — an estimated $94K sold.

Bailard first reported a position in AKBA in Q1 2019 and held it in 4 quarters. The position peaked at $122K in Q1 2019. 155 funds tracked by Wall St. Rank hold AKBA as of Q1 2020.

  • Bailard reported no remaining Akebia Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Bailard sold 14,900 Akebia Therapeutics shares in Q1 2020, an estimated $94K.
  • Bailard first reported a position in Akebia Therapeutics in Q1 2019 and held it in 4 quarters.
  • Bailard's Akebia Therapeutics position peaked at $122K in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2020.

Based on Bailard's 13F filing for Q1 2020, filed 16 Apr 2020.